相关临床试验
74
9 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1955
进行中（未招募）
1
1.4%
已完成
15
20.3%
尚未招募
8
10.8%
招募中
11
14.9%
暂停
1
1.4%
Unknown
38
51.4%
暂无批准数据
- A 24-week randomized clinical trial of 120 patients found that a traditional Chinese herbal formula significantly improved kidney function markers compared to standard irbesartan therapy in diabetic kidney disease. - While both treatments achieved similar reductions in urinary protein levels, the herbal formulation increased estimated glomerular filtration rate and decreased serum creatinine levels, unlike the control group. - Mechanistic studies revealed the herbal therapy reduces inflammatory mediators CX3CL1 and MCP-1, targeting inflammation-driven kidney injury through specific cell populations. - The findings suggest targeting inflammation may offer a complementary therapeutic strategy for preserving renal function in diabetic kidney disease patients.
- A meta-analysis of 24 studies reveals a 37% placebo response rate in irritable bowel syndrome (IBS) patients treated with herbal placebos. - Abdominal pain improvement was noted in 29% of IBS patients receiving herbal placebos, while stool improvement was observed in 46%. - Research location and treatment duration significantly influenced the placebo response, highlighting heterogeneity in IBS clinical trials. - The inclusion of low-dose herbal ingredients in placebos did not amplify the therapeutic effect, suggesting other factors drive the response.
